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Letter to the Editor
In vitro  activity  of  non-bactericidal  concentrations  of
polymyxin B  in combination  with  other antimicrobials
against OXA-23-producing  carbapenem-resistant
Acinetobacter baumannii
Dear Editor,
Acinetobacter baumannii is a major nosocomial pathogen
and carbapenems are the mainstream agents against these
organisms.1 However, carbapenem-resistant A. baumannii
(CRAB) isolates have become widely disseminated owing to
the emergence of Class D carbapenemases, mainly OXA-23,
which  are highly prevalent in Brazil.1
Polymyxins B and colistin are often the last therapeutic
options against CRAB isolates.2 The combination of polymyx-
ins  with another antimicrobial has been proposed to overcome
some  shortcomings of polymyxins in monotherapy, including
the  potential for the emergence of hetero-resistant subpop-
ulations  and a possible limited bactericidal activity in vivo,
considering recent pharmacokinetics studies.2
In vitro studies may  provide some support deﬁning that
candidate antimicrobials would more  likely present a beneﬁ-
cial  effect when combined with polymyxins. We  evaluated the
combination  of non-bactericidal concentrations of polymyxin
B,  which are also more  likely to be clinically achieved,2 with
other  antimicrobials in concentrations usually reached with
common  dosage regimes against OXA-23-producing A. bau-
mannii  isolates.
Two  distinct CRAB strains positive for blaOXA-51 and
blaOXA-23 genes, as characterized elsewhere,1 recovered from
patients admitted at Porto Alegre hospitals between 2007 and
2008  were  selected. MICs of antimicrobials were determined
by  broth microdilution method according to the Clinical and
Laboratory  Standards Institute.3
Time-kill studies (TKS) with polymyxin B at 1× MIC for
strain  01, and 1/4, 1/2 and 1× MIC  for strain 02 were  per-
formed in combination with ﬁxed concentrations of imipenem
(4  mg/L), meropenem (4 mg/L), rifampicin (1 mg/L), tigecycline
(1  mg/L), amikacin (16 mg/L) and ceftazidime (mg/L). All exper-
iments  were performed in duplicate.
Tubes with freshly cation-adjusted Muller-Hinton broth
(CAMHB) with no antibiotic (growth control) and withthe  antibiotic concentrations described above, alone or in
combination, were prepared. Colonies were suspended in 5 mL
of CAMHB and were allowed to grow to a log phase. The
ﬁnal  inoculum of approximately 5 × 105 colony-forming units
(CFU)/mL  containing the drugs was incubated in a shaking
water  bath at 35 ◦C in ambient air. Samples were  removed from
each  bottle at 0, 30 min, 1, 4, 12 and 24 h. Serial 10-fold dilutions
(10−1 to 10−8) were performed in 0.9% sterile sodium chloride
solution. Aliquots of 10 L were plated on agar plate with 5%
sheep  blood. Plates were incubated for 24 h at 35 ◦C.4 Colony
counts  were averaged between the duplicate plates for each
experiment.  A growth control was  included with each iso-
lated  tested. Quality control was  performed using Pseudomonas
aeruginosa ATCC 27853 and Enterococcus faecalis ATCC 29212.
The  MICs of the strains 01 and 02, respectively, for the fol-
lowing  drugs were  0.25 and 2 mg/L for polymyxin B, 32 and
16  mg/L for imipenem and >512 and 16 mg/L for amikacin.
Both strains had MICs of 32 for meropenem and ceftazidime,
≤0.0625 for tigecycline and ≥32 mg/L for rifampicin.
In  TKS, no antimicrobial alone showed bactericidal activity
against  any of the CRAB strains. The 24-h changes in bacte-
rial  count after exposure to polymyxin B combined with other
antimicrobials of the two CRAB strains are displayed in Table 1.
Our  study showed that either of tigecycline, amikacin or
rifampicin  could make the most active agent in combination
with  polymyxin B, showing bactericidal effects against both
strains,  even at subinhibitory concentrations of polymyxin B
against one strain. Notably, both isolates were highly resis-
tant  to amikacin and rifampicin, but when these drugs at
concentrations lower than their MICs were combined with
polymyxin  B, a strong bactericidal activity was detected.
Synergism between rifampicin and polymyxin B has been pre-
viously demonstrated by TKS,4 but no study had assessed the
combination  of amikacin with polymyxin B against A. bauman-
nii.
The  combination of tigecycline with polymyxin B was
highly  bactericidal against both isolates, even at subinhibitory
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Table 1 – The 24 h change in bacterial count after exposure to polymyxin B combined with other antimicrobials against
the  two strains of carbapenem-resistant Acinetobacter baumannii.
Strain Agent in combination Log  (log10 CFU/mL)a for isolate
Polymyxin B
1/4 × MIC 1/2 × MIC 1 × MIC
01 Meropenem – – −7.9977082
Imipenem – – −0.88345
Ceftazidime – – −0.15101
Tigecycline – – −9.95750177
Amikacin – – −9.11335686
Rifampicin – – −9.931542619
02 Meropenem −1.9256176 0.14272336 −4.7447275
Imipenem 0.17405709 0.30103 −10.042688
Ceftazidime 0.18452443 −0.98097676 −8.2483788
Tigecycline −11.06188073 −11.0122806 −11.11013828
Amikacin  −10.0735774 −10.91833 −11.3776389
Rifampicin −9.96721 −10.0555 −10.2596
–, not performed.
a Log  (ﬁnal inoculum of the combined drugs − ﬁnal inoculum of the most active drug in combination [log10 CFU/mL]). Synergy highlighted in
bold was deﬁned as a ≥2 log10 decrease in colony count after 24 h by the combination compared with the most active single agent. Indifference
was deﬁned as a <2 log10 increase or decrease in colony count at 24 h by the combination compared with that by the most active drug alone.
Antagonism was deﬁned as a ≥2 log10 increase in colony count after 24 h by the combination compared with the most active drug alone.
Bactericidal activity was deﬁned as a ≥3 log10 decrease in colony count after 24 h.4
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5oncentration of the latter drug for one isolate. Actually,
igecycline MICs of our CRAB isolates were  very low, but
igecycline presents only bacteriostatic activity in vitro. The
ombination  of this drug with polymyxins has been pre-
iously  assessed against Enterobacteriaceae and only in one
xperimental study with A. baumannii, with synergistic effects
emonstrated.5
Beta-lactams agents were  less effective in our study in com-
ination  with polymyxin B, with no drug showing synergistic
ffect  when combined with subinhibitory concentration of
olymyxin  B. Imipenem and ceftazidime were  only synergistic
or  strain 2.
Although our study was  limited by the evaluation of only
wo  strains, it assessed the combination of polymyxin B
ith  several classes of drugs, only at non-bactericidal con-
entrations  of each drug alone. It also provided data about
XA-23-producing isolates, which is the most common mech-
nism  determining carbapenem resistance in A. baumannii
orldwide.1
In summary, tigecycline, amikacin and rifampicin were
he  most active agents in combination with polymyxin B, as
emonstrated by a strong bactericidal effect even at subin-
ibitory  concentration of the latter. These agents may  show
 beneﬁcial effect when combined with polymyxin B in
he  treatment of OXA-23-producing CRAB and it warrants
onﬁrmation in further experimental and clinical stud-
es.
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